kegg.jp

KEGG DRUG: Talimogene laherparepvec

KEGG   DRUG: Talimogene laherparepvec
Entry

D09966                      Drug                                   

Name

Talimogene laherparepvec (USAN);
Talminogene laherparepvec;
Imlygic (TN);
Oncovex (TN)

Product
Remark
ATC code: L01XL02
Product: D09966<US>
Efficacy

Antineoplastic, Oncolytic virus

  Disease

Melanoma [DS:H00038]

  Type

Gene therapy product

Comment

Oncolytic herpes simplex virus type 1 (HSV1) expressing GM-CSF [HSA:1437]

Interaction
Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XL Antineoplastic cell and gene therapy
     L01XL02 Talimogene laherparepvec
      D09966  Talimogene laherparepvec (USAN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antineoplastics, Other
   Antineoplastics, Miscellaneous
    Talimogene Laherparepvec
     D09966  Talimogene laherparepvec (USAN)
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D09966
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09966
 Cellular and gene therapy products
  D09966
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09966

Other DBs
CAS: 1187560-31-1
PubChem: 124490634
LinkDB

» Japanese version   » Back